ArticleHeadache2026

A phase 1, multicenter, open-label study to evaluate the pharmacokinetics, safety, and tolerability of a single dose of rimegepant in children (aged ≥6 to <12 years) with a history of migraine.

Chay Ngee Lim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.